Classic Congenital Adrenal Hyperplasia Cah — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for classic congenital adrenal hyperplasia cah . 16 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
16
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Classic Congenital Adrenal Hyperplasia Cah

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Neurocrine 16 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating classic congenital adrenal hyperplasia cah . Each bar = one year. Y-axis scaled to peak year (12 patents).

12
35
4
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Crenessity
CRINECERFONT
 Neurocrine 16 75 — 2035-01-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11311544 Crenessity method of use 75 2035-01-21
11311544 Crenessity method of use 75 2035-01-21
11730739 Crenessity method of use 75 2035-01-21
11730739 Crenessity method of use 75 2035-01-21
10905690 Crenessity method of use 75 2035-01-21
10905690 Crenessity method of use 75 2035-01-21
11311544 Crenessity method of use 75 2035-01-21
11730739 Crenessity method of use 75 2035-01-21
11730739 Crenessity method of use 75 2035-01-21
10905690 Crenessity method of use 75 2035-01-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12128033 Crenessity method of use 75 2041-06-09
12128033 Crenessity method of use 75 2041-06-09
12128033 Crenessity method of use 75 2041-06-09
12128033 Crenessity method of use 75 2041-06-09
10905690 Crenessity method of use 75 2035-01-21
10905690 Crenessity method of use 75 2035-01-21
11311544 Crenessity method of use 75 2035-01-21
11730739 Crenessity method of use 75 2035-01-21
11311544 Crenessity method of use 75 2035-01-21
11730739 Crenessity method of use 75 2035-01-21

Related